Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 12, 2020 at 10:58 pm
Share
Formosa Laboratories, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was TWD 787.707 million compared to TWD 594.045 million a year ago. Operating loss was TWD 49.020 million compared to TWD 20.598 million a year ago. Net income was TWD 534.173 million compared to net loss of TWD 118.942 million a year ago. Basic earnings per share was TWD 4.99 compared to basic loss per share of TWD 1.2 a year ago. Diluted earnings per share was TWD 4.49 compared to diluted loss per share of TWD 1.2 a year ago. For the half year, sales was TWD 1,450.350 million compared to TWD 1,248.367 million a year ago. Operating loss was TWD 97.435 million compared to TWD 117.797 million a year ago. Net income was TWD 432.293 million compared to net loss of TWD 86.801 million a year ago. Basic earnings per share was TWD 4.2 compared to basic loss per share of TWD 0.88 a year ago. Diluted earnings per share was TWD 3.78 compared to diluted loss per share of TWD 0.88 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
